Abstract
Vaccines and chemotherapy have undeniably been the discoveries in the field of biomedical research that have exerted the biggest impact on the improvement of public health. Nevertheless, the development of bacterial resistance to antibiotics has co-evolved over time with the discovery of new drugs. This entails the necessity for continuous research on new anti-infectious agents.The current review highlights recent discoveries in the molecular mechanisms of specific host pathogen interactions and their potential for drug discovery. The focus is on facultative and obligate intracellular pathogens (Mycobacterium, Chlamydia and Legionella) and their manipulation of host cells in regard to inhibition of phagosome maturation and cell death. Furthermore, the composition and role of the SecA2 and the ESX-1 secretion pathways in bacterial virulence and manipulation of infected host cells is discussed. The central hypothesis proposed in this review is that the characterization of bacterial proteins and lipids involved in host cell manipulation (modulins) will provide an abundance of new drug targets. One advantage of targeting such bacterial modulins for drug development is that these anti-modulin drugs will not disrupt the beneficial host microflora and therefore have fewer side effects.
Keywords: Apoptosis, phagosome, mycobacterium, secretion, cell wall, antibiotics, drug resistance, infection, modulin
Current Drug Targets
Title: Molecular Mechanisms of Host-Pathogen Interactions and their Potential for the Discovery of New Drug Targets
Volume: 9 Issue: 2
Author(s): Volker Briken
Affiliation:
Keywords: Apoptosis, phagosome, mycobacterium, secretion, cell wall, antibiotics, drug resistance, infection, modulin
Abstract: Vaccines and chemotherapy have undeniably been the discoveries in the field of biomedical research that have exerted the biggest impact on the improvement of public health. Nevertheless, the development of bacterial resistance to antibiotics has co-evolved over time with the discovery of new drugs. This entails the necessity for continuous research on new anti-infectious agents.The current review highlights recent discoveries in the molecular mechanisms of specific host pathogen interactions and their potential for drug discovery. The focus is on facultative and obligate intracellular pathogens (Mycobacterium, Chlamydia and Legionella) and their manipulation of host cells in regard to inhibition of phagosome maturation and cell death. Furthermore, the composition and role of the SecA2 and the ESX-1 secretion pathways in bacterial virulence and manipulation of infected host cells is discussed. The central hypothesis proposed in this review is that the characterization of bacterial proteins and lipids involved in host cell manipulation (modulins) will provide an abundance of new drug targets. One advantage of targeting such bacterial modulins for drug development is that these anti-modulin drugs will not disrupt the beneficial host microflora and therefore have fewer side effects.
Export Options
About this article
Cite this article as:
Briken Volker, Molecular Mechanisms of Host-Pathogen Interactions and their Potential for the Discovery of New Drug Targets, Current Drug Targets 2008; 9(2) . https://dx.doi.org/10.2174/138945008783502449
DOI https://dx.doi.org/10.2174/138945008783502449 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
3D-QSAR Study on Ring Substituted Imidazoles for Their Antitubercular Activity
Letters in Drug Design & Discovery Attack on the Scourge of Tuberculosis: Patented Drug Targets
Recent Patents on Anti-Infective Drug Discovery MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Current Pharmaceutical Design of Antituberculosis Drugs: Future Perspectives
Current Pharmaceutical Design Simultaneously Determining Seven Second-Line Anti-TB Drugs by UHPLC- MS: Application for TDM in HIV-TB Patients
Current Pharmaceutical Analysis Antimycotic Drugs and their Mechanisms of Resistance to <i>Candida</i> Species
Current Drug Targets Calcium Oxide Catalyzed Synthesis of Chalcone Under Microwave Condition
Current Microwave Chemistry Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases
Current Pharmaceutical Design Patent Selections
Recent Patents on Drug Delivery & Formulation Effect of Contrast-enhanced Contemporaneous <sup>18</sup>F-FDG PET/CT on Semi Quantification Uptake Value Using Third Party Viewing Workstation
Recent Patents on Medical Imaging Microwave-Assisted Synthesis, Antimicrobial and Cytotoxic Activities of Some 4-Thioxo-Thiazolidine-2-One Derivatives
Letters in Drug Design & Discovery Repurposing of Fluvastatin Against Candida albicans CYP450 Lanosterol 14 α-demethylase, a Target Enzyme for Antifungal Therapy: An In silico and In vitro Study
Current Molecular Medicine An Unprecedented Revolution in Medicinal Chemistry Driven by the Progress of Biological Science
Current Topics in Medicinal Chemistry Meet Our Associate Editor
Current Drug Metabolism Differential Gene Expression of <i>ASUN, NEMF, PTPRC</i> and <i>DHX29</i>: Candidate Biomarkers for the Diagnosis of Active and Latent Tuberculosis
Infectious Disorders - Drug Targets Innate T-Cell Immunity in HIV Infections: The Role of Vg9Vd2 T Lymphocytes
Current Molecular Medicine Recent Developments in Antimalarial Drug Discovery
Anti-Infective Agents in Medicinal Chemistry Meet Our Editorial Board Member
The Natural Products Journal Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design